Abstract In 1959, 5-iodo-2′-deoxyuridine (IDU) was described, the first antiviral drug ever to
be (and still) marketed (for the topical treatment of herpetic keratitis). Now 50 years following …

The majority of the antiviral drugs that have been licensed for clinical use or are being
considered for clinical use are pyrimidine nucleoside analogues and these compounds are …

CASE STUDY normal vital signs and no abnormalities. White blood cell count is 5800
cells/mm3 with a normal differential, hemoglobin is 11.8 g/dL, all liver tests are within normal …

The initial development of antiviral compounds was slow, with the first clinical antiviral agent
not available until the 1960s. Early development was hindered by the lack of understanding …

As has been established in rabbits,(E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) is
superior to 5-iodo-2′-deoxyuridine (IDU) in the topical treatment of epithelial HSV-1 …

The antiviral activity spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVdU) is not
restricted to herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) but also …

The quiet pandemic of herpes simplex virus (HSV) infection has plagued humanity since
ancient times, causing mucocutaneous infection, such as herpes labialis and herpes …

Skip the header click to show the menu Menu Cart Login Login/Register Institutional Access
Access Options Enter words / phrases / DOI / ISBN / keywords / authors / etc Search Advanced …

Abstract (E)‐5‐(2‐bromovinyl)‐2′‐deoxyuridine (BVDU, Brivudin, Zostex®, Zerpex®,
Zonavir®), now more than 20 years after its discovery, still stands out as a highly potent and …

In 1959 Bill Prusoff described the synthesis of idoxuridine (5-iodo-2 0-deoxyuridine, IDUa), 1
later to become the first antiviral drug to be licensed for clinical use. This marked the birthday …